Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
94 hedge funds and large institutions have $549M invested in Adverum Biotechnologies in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 13 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
164% more capital invested
Capital invested by funds: $208M → $549M (+$341M)
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
43% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $869K
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
13% more funds holding
Funds holding: 83 → 94 (+11)
0.98% more ownership
Funds ownership: 6.28% → 7.27% (+0.98%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$29M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.89M |
| 3 |
O
OrbiMed
New York
|
+$5.93M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$5.18M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$5.42M |
| 2 |
B
Bpifrance
Maisons Alfort, Cedex,
France
|
-$4.34M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.53M |
| 4 |
WM
WS Management
Jacksonville,
Florida
|
-$2.27M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.1M |
ADVM Hedge Fund Activity: Q2 2019 in Review
94 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2019, worth a combined $549M — up 164% from $208M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ADVM positions and 13 closed out — a net gain of 14 holders — while 29 added to existing stakes and 23 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $29M. The largest seller was JP Morgan Chase, cutting an estimated $5.42M.
- 94 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2019, up from 83 in Q1 2019.
- Funds reported $549M of Adverum Biotechnologies stock for Q2 2019, up 164% quarter-over-quarter.
- 27 funds opened new Adverum Biotechnologies positions in Q2 2019 and 13 closed out, a net change of +14 holders.
- The largest Adverum Biotechnologies buyer in Q2 2019 was Avoro Capital Advisors, an estimated $29M added.
- The largest Adverum Biotechnologies seller in Q2 2019 was JP Morgan Chase, an estimated $5.42M sold.
Based on aggregated 13F filings for Q2 2019.